Details of the Drug

General Information of Drug (ID: DM75RFJ)

Drug Name
Siplizumab
Synonyms Siplizumab (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 2 [1]
Psoriasis vulgaris EA90 Discontinued in Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB06371
TTD ID
D0A7NB
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface antigen CD2 (CD2) TTJDUNO CD2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28.
2 Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.